Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Gives Nucala Initial OK In Severe Asthma After GSK Offers Price Cut

Executive Summary

Adult patients with severe eosinophilic asthma in England and Wales look set to get a much needed treatment option following NICE's provisional backing of GlaxoSmithKline's new MAb therapy.

You may also be interested in...

Glaxo Set To File Nucala In COPD, Despite Mixed Phase III Results

An 'imperfect biomarker' – that's how a New England Journal of Medicine editorial describes the eosinophil count used in METREX and METREO studies.

GSK's Nucala Shows Promise In A Rare Systemic Vasculitis

GlaxoSmithKline is cementing its leadership position in eosinophilic conditions with promising pivotal results with Nucala as an add-on therapy for the rare disorder eosinophilic granulomatosis with polyangiitis. The development is expected to lead to an extension of its indications.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts